FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308255050> ?p ?o ?g. }

• W4308255050 endingPage "2257" @default.
• W4308255050 startingPage "2247" @default.
• W4308255050 abstract "Significance Statement Several reports have described glomerular disease relapse after coronavirus disease 2019 (COVID-19) vaccination, but without proper controls, determining whether this association is real or due to chance is not possible. In this population-level cohort of 1105 adult patients with stable glomerular disease, a first dose of a COVID-19 vaccine was not associated with relapse risk; however, receiving a subsequent vaccine dose was associated with a two-fold higher risk of relapse. The increase in absolute risk associated with vaccination was low (1%–5%), and the majority of affected patients did not require a change in immunosuppression or biopsy. These results represent the first accurate assessment of the relative and absolute risks of glomerular disease flare associated with COVID-19 vaccination and underscore the favorable risk-benefit profile of vaccination in patients with glomerular disease. Background Although case reports have described relapses of glomerular disease after COVID-19 vaccination, evidence of a true association is lacking. In this population-level analysis, we sought to determine relative and absolute risks of glomerular disease relapse after COVID-19 vaccination. Methods In this retrospective population-level cohort study, we used a centralized clinical and pathology registry (2000–2020) to identify 1105 adult patients in British Columbia, Canada, with biopsy-proven glomerular disease that was stable on December 14, 2020 (when COVID-19 vaccines first became available). The primary outcome was disease relapse, on the basis of changes in kidney function, proteinuria, or both. Vaccination was modeled as a 30-day time-varying exposure in extended Cox regression models, stratified on disease type. Results During 281 days of follow-up, 134 (12.1%) patients experienced a relapse. Although a first vaccine dose was not associated with relapse risk (hazard ratio [HR]=0.67; 95% confidence interval [95% CI], 0.33 to 1.36), exposure to a second or third dose was associated with a two-fold risk of relapse (HR=2.23; 95% CI, 1.06 to 4.71). The pattern of relative risk was similar across glomerular diseases. The absolute increase in 30-day relapse risk associated with a second or third vaccine dose varied from 1%–2% in ANCA-related glomerulonephritis, minimal change disease, membranous nephropathy, or FSGS to 3%–5% in IgA nephropathy or lupus nephritis. Among 24 patients experiencing a vaccine-associated relapse, 4 (17%) had a change in immunosuppression, and none required a biopsy. Conclusions In a population-level cohort of patients with glomerular disease, a second or third dose of COVID-19 vaccine was associated with higher relative risk but low absolute increased risk of relapse." @default.
• W4308255050 created "2022-11-09" @default.
• W4308255050 creator A5003186442 @default.
• W4308255050 creator A5009962306 @default.
• W4308255050 creator A5014099876 @default.
• W4308255050 creator A5017932611 @default.
• W4308255050 creator A5027641313 @default.
• W4308255050 creator A5044179329 @default.
• W4308255050 creator A5067237284 @default.
• W4308255050 creator A5070922317 @default.
• W4308255050 date "2022-12-01" @default.
• W4308255050 modified "2023-10-17" @default.
• W4308255050 title "A Population-Based Analysis of the Risk of Glomerular Disease Relapse after COVID-19 Vaccination" @default.
• W4308255050 cites W1966416547 @default.
• W4308255050 cites W2026274122 @default.
• W4308255050 cites W2155965977 @default.
• W4308255050 cites W2162337442 @default.
• W4308255050 cites W2514959212 @default.
• W4308255050 cites W2519433651 @default.
• W4308255050 cites W2922192032 @default.
• W4308255050 cites W3007483251 @default.
• W4308255050 cites W3085025551 @default.
• W4308255050 cites W3093367571 @default.
• W4308255050 cites W3111255098 @default.
• W4308255050 cites W3115059693 @default.
• W4308255050 cites W3131688063 @default.
• W4308255050 cites W3137688158 @default.
• W4308255050 cites W3157055558 @default.
• W4308255050 cites W3158373340 @default.
• W4308255050 cites W3165733586 @default.
• W4308255050 cites W3176910499 @default.
• W4308255050 cites W3194862672 @default.
• W4308255050 cites W3200479416 @default.
• W4308255050 cites W3200535500 @default.
• W4308255050 cites W3200553460 @default.
• W4308255050 cites W3203360791 @default.
• W4308255050 cites W3206956654 @default.
• W4308255050 cites W3209430876 @default.
• W4308255050 cites W3214136149 @default.
• W4308255050 cites W4200533211 @default.
• W4308255050 cites W4205483821 @default.
• W4308255050 doi "https://doi.org/10.1681/asn.2022030258" @default.
• W4308255050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36332971" @default.
• W4308255050 hasPublicationYear "2022" @default.
• W4308255050 type Work @default.
• W4308255050 citedByCount "20" @default.
• W4308255050 countsByYear W43082550502022 @default.
• W4308255050 countsByYear W43082550502023 @default.
• W4308255050 crossrefType "journal-article" @default.
• W4308255050 hasAuthorship W4308255050A5003186442 @default.
• W4308255050 hasAuthorship W4308255050A5009962306 @default.
• W4308255050 hasAuthorship W4308255050A5014099876 @default.
• W4308255050 hasAuthorship W4308255050A5017932611 @default.
• W4308255050 hasAuthorship W4308255050A5027641313 @default.
• W4308255050 hasAuthorship W4308255050A5044179329 @default.
• W4308255050 hasAuthorship W4308255050A5067237284 @default.
• W4308255050 hasAuthorship W4308255050A5070922317 @default.
• W4308255050 hasConcept C126322002 @default.
• W4308255050 hasConcept C203014093 @default.
• W4308255050 hasConcept C22070199 @default.
• W4308255050 hasConcept C2778653478 @default.
• W4308255050 hasConcept C2779134260 @default.
• W4308255050 hasConcept C2780252810 @default.
• W4308255050 hasConcept C2908647359 @default.
• W4308255050 hasConcept C71924100 @default.
• W4308255050 hasConcept C72563966 @default.
• W4308255050 hasConcept C99454951 @default.
• W4308255050 hasConceptScore W4308255050C126322002 @default.
• W4308255050 hasConceptScore W4308255050C203014093 @default.
• W4308255050 hasConceptScore W4308255050C22070199 @default.
• W4308255050 hasConceptScore W4308255050C2778653478 @default.
• W4308255050 hasConceptScore W4308255050C2779134260 @default.
• W4308255050 hasConceptScore W4308255050C2780252810 @default.
• W4308255050 hasConceptScore W4308255050C2908647359 @default.
• W4308255050 hasConceptScore W4308255050C71924100 @default.
• W4308255050 hasConceptScore W4308255050C72563966 @default.
• W4308255050 hasConceptScore W4308255050C99454951 @default.
• W4308255050 hasIssue "12" @default.
• W4308255050 hasLocation W43082550501 @default.
• W4308255050 hasLocation W43082550502 @default.
• W4308255050 hasOpenAccess W4308255050 @default.
• W4308255050 hasPrimaryLocation W43082550501 @default.
• W4308255050 hasRelatedWork W2012225890 @default.
• W4308255050 hasRelatedWork W2034212555 @default.
• W4308255050 hasRelatedWork W2061396063 @default.
• W4308255050 hasRelatedWork W2356894405 @default.
• W4308255050 hasRelatedWork W2410991317 @default.
• W4308255050 hasRelatedWork W2418946042 @default.
• W4308255050 hasRelatedWork W2497092908 @default.
• W4308255050 hasRelatedWork W3149337076 @default.
• W4308255050 hasRelatedWork W4320041232 @default.
• W4308255050 hasRelatedWork W4386893802 @default.
• W4308255050 hasVolume "33" @default.
• W4308255050 isParatext "false" @default.
• W4308255050 isRetracted "false" @default.
• W4308255050 workType "article" @default.